Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AGXSWX:BAYN 50 EV-to-Revenue is 1.71 as of Sep. 21, 2026, which is 43% above its 10-year median of 1.20. GuruFocus rates XSWX:BAYN with a GF Score™ of 50/100 and a GF Value™ of CHF24.73 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 965 Drug Manufacturers companies, Bayer AG ranks better than 63.63% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bayer AG's enterprise value is CHF71,921 Mil.
Bayer AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was CHF41,955 Mil. Therefore, Bayer AG's EV-to-Revenue for today is 1.71.
The historical rank and industry rank for Bayer AG's EV-to-Revenue or its related term are showing as below:
XSWX:BAYN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.27 Med: 1.2 Max: 2.81
Current: 1.68
During the past 13 years, the highest EV-to-Revenue of Bayer AG was 2.81. The lowest was 0.27. And the median was 1.20.
XSWX:BAYN's EV-to-Revenue is ranked better than 63.63% of 965
companies
in the Drug Manufacturers industry
Industry Median: 2.45
vs XSWX:BAYN: 1.68
As of today (2026-09-21), Bayer AG's stock price is CHF46.34.
Bayer AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF42.71. Therefore, Bayer AG's PS Ratio for today is 1.09.
Bayer AG's share price for today is CHF46.34.
Bayer AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF42.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG EV-to-Revenue Related Terms
Bayer AG EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Bayer AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: EV-to-Revenue Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EV-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Bayer AG's EV-to-Revenue falls into.
Bayer AG's current Enterprise Value is CHF71,921 Mil.
Bayer AG's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF41,955 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a EV-to-Revenue of 1.71 as of Sep. 21, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Bayer AG and its competitors. This is 43% above median its historical median of 1.20. Over the past decade, Bayer AG's EV-to-Revenue has ranged from 0.27 to 2.81. According to the industry distribution chart, Bayer AG ranks #351 out of 965 companies in the Drug Manufacturers industry, placing it in the top 36.4%.
Is Bayer AG's EV-to-Revenue too high?
Bayer AG's current EV-to-Revenue of 1.71 is 43% above median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.81. The Drug Manufacturers industry median EV-to-Revenue is 2.45. Bayer AG's value of 1.71 is 30.2% below this industry median. Based on the distribution chart, Bayer AG ranks #351 out of 965 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bayer AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EV-to-Revenue compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #351 out of 965 companies for EV-to-Revenue. This puts Bayer AG in the upper half of its industry. The industry median EV-to-Revenue is 2.45. Bayer AG's value of 1.71 is 30.2% below this benchmark. Historically, Bayer AG's own EV-to-Revenue has ranged from 0.27 to 2.81 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 2.45, Bayer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Drug Manufacturers company?
The median EV-to-Revenue among Drug Manufacturers companies is 2.45, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current EV-to-Revenue of 1.71 is 30.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median EV-to-Revenue is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EV-to-Revenue is 1.71, which is 43% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.73, compared to a current price of CHF46.34 — trading 87.4% above its estimated fair value. The current EV-to-Revenue is 1.71, which is 43% above median its 10-year median of 1.20 and 30.2% below the Drug Manufacturers industry median of 2.45. Bayer AG's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current EV-to-Revenue is 1.71 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF46.34 is trading 87.4% above its estimated GF Value™ of CHF24.73.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
EV-to-Revenue: 1.71 (43% above median its 10-year median of 1.20)
GF Value™: CHF24.73 vs. price of CHF46.34 (87.4% above fair value)
Industry Position: 30.2% below the Drug Manufacturers median (#351 of 965)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
50GF Score
Get the complete analysis for XSWX:BAYN
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
